Subscribe for <a href="BIOTECHBLUEPRINT.SUBSTACK.COM" target="_blank" rel="noopener noreferer">FREE HERE</a>.FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).

Subscribe for FREE HERE. FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).

Subscribe for <a href="BIOTECHBLUEPRINT.SUBSTACK.COM" rel="noopener noreferrer">FREE HERE</a>.FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).

FDA Drama & Psychedelic Setback — This Week in Biotech #58

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.

For more content, please subscribe to biotechblueprint.substack.com.

Technology

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Share FDA Drama & Psychedelic Setback — This Week in Biotech #58

Sign up to save your podcasts

FDA Drama & Psychedelic Setback — This Week in Biotech #58

FDA Drama & Psychedelic Setback — This Week in Biotech #58